SLC5A2 and cardiovascular disorder: Sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists have recently been recommended for treatment of T2D in subjects with cardiovascular disease (6).